Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.24
- Piotroski Score 2.00
- Grade Outperform
- Symbol (NUVB)
- Company Nuvation Bio Inc.
- Price $2.81
- Changes Percentage (-2.6%)
- Change -$0.08
- Day Low $2.75
- Day High $2.94
- Year High $4.16
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.50
- High Stock Price Target $10.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.32
- Trailing P/E Ratio -8.66
- Forward P/E Ratio -8.66
- P/E Growth -8.66
- Net Income $-75,802,000
Income Statement
Quarterly
Annual
Latest News of NUVB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We Think Nuvation Bio (NYSE:NUVB) Can Easily Afford To Drive Business Growth
Investing in unprofitable businesses like biotech and mining exploration can be lucrative, but many companies end up bankrupt due to cash burn. Nuvation Bio (NYSE:NUVB) has a cash runway of 9.3 years,...
By Yahoo! Finance | 1 month ago
